Thank you for visiting Kolon Life Science.
Though faced with rapid changes in our business environment, we at Kolon Life Science intend on continually striving to challenge ourselves to new disciplines and identify new possibilities.
Our company’s vision is to build up off of the growth and profitability of our existing API and eco-chemical businesses and step up efforts in the development of new biopharmaceutical products to ultimately emerge as a global leader in biotechnology.
Currently, we are in the midst of developing the world’s first allogeneic cell therapy for the treatment of osteoarthritis, a degenerative joint disease affecting an increasing number of patients, especially among rapidly aging populations. TissueGene-C (InvossaTM) is an innovative drug unlike any other existing treatment methods, and upon launch would offer substantial cost savings for patients worldwide.
We are also focused on continuing with our R&D efforts in the field of gene therapeutics, with plans for introducing new drugs offering pain relief and vaccines for cancer patients.
Moreover, we remain committed to bringing about innovative changes to our existing businesses as well, and plan on maintaining growth and stability by further expanding the market for pharmaceutical products in Japan, increasing collaboration with our global partners, and launching new products.
Even a single missing piece would result in an incomplete puzzle. We at Kolon Life Science intend on making every effort to leave no new possibility unexamined in realizing our future vision.